Surgery (Lund)
101 – 110 of 1754
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Impact of autofluorescence for detection of parathyroid glands during thyroidectomy on postoperative parathyroid hormone levels : parallel multicentre randomized clinical trial
(
- Contribution to journal › Article
-
Mark
Portal vein embolization with N-butyl-cyanoacrylate improves liver hypertrophy compared to microparticles – A Swedish multicenter cohort study
(
- Contribution to journal › Article
-
Mark
Clinical use of an emergency manual by resuscitation teams and impact on performance in the emergency department : A prospective mixed-methods study protocol
(
- Contribution to journal › Article
-
Mark
Protocol for the T-REX-trial : Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases - An open, multicentre, randomised non-inferiority phase 3 trial
(
- Contribution to journal › Article
-
Mark
Predictive Factors for Delayed Gastric Emptying After Pancreatoduodenectomy : A Swedish National Registry-Based Study
(
- Contribution to journal › Article
-
Mark
Role of hospital and patient factors in the outcome of reoperations for primary hyperparathyroidism : a retrospective multicenter cohort study
(
- Contribution to journal › Article
-
Mark
The role of 18F-fluoromethylcholine-positron emission tomography-computed tomography for preoperative localization of hyperfunctioning parathyroid glands with special emphasis on multiglandular disease : a retrospective cohort study
(
- Contribution to journal › Article
-
Mark
Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study
(
- Contribution to journal › Article
-
Mark
Noninvasive Staging of Lymph Node Status in Breast Cancer Using Machine Learning : External Validation and Further Model Development
(
- Contribution to journal › Article
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
(
- Contribution to journal › Article